CHRONIC ILLNESS, HOSPITALIZATION AND CHILD

Duygusal sorunlar, kronik hastalığa sahip çocuk ve ergenler ve ailelerde evrensel anlam taşımamalarına karşın, araştırmalardan gelen kanıtlar; kronik pediatrik hastalıkların psikolojik bozukluklar için esas bir risk etkeni oluşturduğunu göstermiştir. Kronik hastalıklarla beraber olan psikolojik sorunlarla sıklıkla ruh sağlığı konsultanları yüzleşirler. Bunları tanımlamak için bir yapıya ihtiyaç vardır. Hasta değerlendirilirken, klinisyenler, en azından teorik olarak, psikosomatik komponentin kronik hastalıkların her fazında var olacağını mutlaka hatırlamalıdırlar. Kronik hastalığa tepki, bireysel, gelişimsel ve çevresel etmenlerden etkilenir. Etkin psikiyatrik konsultasyon ve psikolojik yardım kronik hastalıkların tedavisi sırasında daha iyi prognoz ve uyuma yol açabilir. Although emotional disturbances do not mean universal in chronically ill children and adolescents and their families, the evidence from studies indicated that the chronic pediatric illness constitutes a substantial risk factor for psychological disorder. Psychological problems associated with chronic illness frequently confront the mental health consultant, and a framework for conceptualizing them is required. In evaluating a patient, the clinicians must remember that a psychosomatic component is at least theoretical possible in every phase of all chronic disorders. Reacting to the chronic illness is influenced by individual, developmental and environmental factors The effective psychiatric consultation and psychological support can lead to better prognosis and compliance during the treatment of chronic illness

Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases

Attention deficit/hyperactivity disorder is one of the most common neurodevelopmental disorders. The pathophysiology is thought to involve noradrenaline and dopamine. The role of dopamine transporter (DAT) was evaluated in imaging studies using mostly dopamine reuptake inhibitors. Atomoxetine is a selective noradrenaline reuptake inhibitor. Here we report the results of a pilot study conducted to evaluate changes in striatal DAT after 8 weeks of atomoxetine treatment. Our results suggest that 8 weeks of atomoxetine treatment may change striatal DAT bioavailability as measured via SPECT but that change was not correlated with genotype or clinical improvement

Parental psychological distress associated with COVID-19 outbreak: A large-scale multicenter survey from Turkey

Aims: Pandemics can cause substantial psychological distress; however, we do not know the impact of the COVID-19 related lockdown and mental health burden on the parents of school age children. We aimed to comparatively examine the COVID-19 related the stress and psychological burden of the parents with different occupational, locational, and mental health status related backgrounds. Methods: A large-scale multicenter online survey was completed by the parents (n = 3,278) of children aged 6 to 18 years, parents with different occupational (health care workers—HCW [18.2%] vs. others), geographical (İstanbul [38.2%] vs. others), and psychiatric (child with a mental disorder [37.8%]) backgrounds. Results: Multivariable logistic regression analysis showed that being a HCW parent (odds ratio 1.79, p <.001), a mother (odds ratio 1.67, p <.001), and a younger parent (odds ratio 0.98, p =.012); living with an adult with a chronic physical illness (odds ratio 1.38, p <.001), having an acquaintance diagnosed with COVID-19 (odds ratio 1.22, p =.043), positive psychiatric history (odds ratio 1.29, p <.001), and living with a child with moderate or high emotional distress (odds ratio 1.29, p <.001; vs. odds ratio 2.61, p <.001) were independently associated with significant parental distress. Conclusions: Parents report significant psychological distress associated with COVID-19 pandemic and further research is needed to investigate its wider impact including on the whole family unit. © The Author(s) 2020